APEX1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using APEX1 mouse mAb against Hela (1), Jurkat (2), SW480 (3), A431 (4), HepG2 (5), NIH/3T3 (6), and PC-12 (7) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using APEX1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of SK-N-SH cells using APEX1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using APEX1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using APEX1 mouse mAb with DAB staining.    

  
  

APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1), also known as APE1 or Ref-1. is a multifunctional enzyme critical for DNA repair and redox regulation. It plays a central role in the base excision repair (BER) pathway, where it cleaves abasic (AP) sites generated during DNA damage repair. Additionally, APEX1 acts as a redox-sensitive chaperone, modulating the DNA-binding activity of transcription factors such as AP-1. p53. and NF-κB by maintaining their reduced states. Its dual functions link APEX1 to genomic stability, oxidative stress response, and cellular homeostasis.

APEX1 antibodies are essential tools for studying these biological processes. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to detect APEX1 expression, localization, and interactions. These antibodies help researchers explore APEX1's roles in cancer progression, neurodegenerative diseases, and aging, where dysregulation of DNA repair or redox signaling is often implicated. Some antibodies specifically target post-translational modifications (e.g., acetylation) or functional domains (e.g., the redox-sensitive N-terminal region), enabling mechanistic studies. Commercial APEX1 antibodies are typically raised in rabbits or mice, with validation in knockout models or siRNA-treated cells to confirm specificity. Due to APEX1's nuclear-cytoplasmic shuttling and stress-dependent expression patterns, antibody selection often depends on experimental context. Reliable APEX1 detection remains vital for understanding its therapeutic potential as a biomarker or target in diseases involving oxidative damage or impaired DNA repair.